Glibenclamide UPS Pharmaceutical Powder CAS 10238-21-8 Glibenclamide
Product Description
Introduction
Product Name: glibenclamide
Specification :99.5%-101%
Test method: HPLC
Appearance:White or almost white crystalline powder
CAS No.:10238-21-8
Glibenclamide COA
ITEM |
STANDARD |
RESULTS |
Appearance |
Crystalline powder |
Conforms |
Melting range |
129°C~132°C |
130.8°C-131°C |
Loss on drying |
≤0.5% |
0.20 % |
Specific rotation |
-58°~-62°(C=1,in CH3OH) |
-61.05° |
Sulphated ash |
≤0.1% |
0.08 % |
Heavy metals |
≤10ppm |
Conforms |
Chlorides |
≤0.02% |
Conforms |
Sulfates |
≤0.02% |
Conforms |
Fluorine |
14.7%~17.9% |
15.2% |
Residual solvent |
Methanol ≤0.2% |
0.0% |
Related substances |
Single impurity ≤0.2% |
0.05% |
Assay |
≥99.5% |
99.92% |
Conclusion |
Accordance with the reference |
|
Function
Hypoglycaemic. Inhibit decomposition of glycogen and Gluconeogenesis, reduce glucoses production and output in liver;Besides, it can strengthen pancreass sensitivity to insulin and consume more sugar,reducing FPG and P2hPG. For the second-generation sulfonylurea drugs, there is a strong role in lowering blood glucose, its hypoglycemic effect than D-860 Strong 100-fold. Fasting blood glucose after treatment compared with postprandial blood glucose significantly decreased, respectively, reduced by about 35%, and 21% or less.Easily absorbed from the gastrointestinal tract, plasma protein binding rate is high.Fall blood sugar function strong, Glyburide capsule: its role a toluene sulfonylurea urea butyl 100 times stronger. Oral 30 minutes later appeared for about 16 ~ role 24 hours. Easily absorbed from the gastrointestinal tract, plasma protein binding rate is high. T1/2 about 10 h. Almost all by hepatic metabolism, the main metabolites hypoglycemic activity is weak. About 50% of metabolites from urine discharge, and another 50% by bile into debris.
Glyburide piece: this product is lowering blood sugar pills. 1. Stimulate pancreatic beta cells secrete insulin, a prerequisite, there is still a beta cell synthesis and secretion of insulin function; Through the increase insulin
levels for the liver or portal vein direct action, inhibit liver glycogen decomposition and glycogen vision, liver function was born generation and output glucose reduced; 3. Also may increase the organization for pancreatic insulin sensitiity and sugar (mainly through the use of possible receptors, therefore, the role) function is reduced fasting blood sugar and blood glucose after a meal.
Application
Acarbose is an anti-diabetic drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes. It is sold in Europe under the brand name Glucobay (Bayer AG), in North America as Precose
(BayerPharmaceuticals), and in Canada as Prandase (Bayer AG). It is an inhibitor of alpha glucosidase, an enteric enzyme that releases glucose from larger carbohydrates.